Sector News

Novartis, Merck and Allergan join Big Pharma’s 2020 price-hike parade

January 6, 2020
Life sciences

The first two days of the New Year ushered in hundreds of price hikes across the drug industry, and the tally has just kept growing.

So far this month, 471 meds have bigger stickers now than they did a week ago, an update from GoodRx shows. On average, the increases came in at 5.1%. And as Reuters reports, Novartis, Merck & Co. and Allergan Friday joined the list of companies raising prices.

Novartis is marking up prices on about 7% of the products it sells in the U.S., a spokesperson told FiercePharma. Overall, the drugmaker expects U.S. net pricing—the amount it reaps after rebates and discounts—to decline by 2.5% during 2020.

Merck is raising prices on about 15 medicines, Reuters reports. The hikes are within the company’s pledge to limit price hikes to U.S. inflation, a spokeswoman said. The drugmaker is “committed to working with policymakers and stakeholders at both the federal and local levels on solutions that will address patient out-of-pocket costs,” she added.

For its part, Allergan is raising prices by 25 drugs by 5%—plus two others by 2% to 3%, a spokeswoman said. The drugmaker still expects net pricing to be flat or decline this year on higher rebates and discounts.

The Friday hikes by Allergan, Merck and Novartis followed similar moves by Pfizer, Bristol-Myers Squibb, AbbVie, Gilead Sciences and others.

The most commonly prescribed drugs carrying higher prices include Pfizer and Bristol-Myers Squibb’s Eliquis, Eli Lilly and Boehringer Ingelheim’s Jardiance, BI’s Tradjenta, Gilead’s Truvada and Pfizer’s Chantix, according to GoodRx.

All but a few of the price hikes are under 10%, a level famously set years back by Allergan CEO Brent Saunders in his pledge about pharma’s “social contract.” Some of them pushed right up to that threshold, though, with increases of 9.9%.

All of the increases apply to list prices, which are negotiated down by middlemen and payers. Patients typically don’t pay list prices.

Still, the steady stream of price hikes has angered lawmakers, patients and public health advocates. Patients 4 Affordable Drugs Executive Director Ben Wakana said in a news statement that the pharma industry “can’t break its addiction to price increases.”

The hikes show the industry can’t be trusted to police itself, Wakana said, adding that it’s time for Congress to pass legislation to stop the industry’s “price gouging.”

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach